BC Extra | Nov 16, 2019
Company News

Nov. 15 Company Quick Takes: Qiagen continues climb after confirming takeout offers; plus Fetroja, selumetinib, PharmAbcine, semaglutide

Qiagen confirms acquisition interest  Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Friday it is reviewing its strategic alternatives after receiving several “non-binding indications of interest for the acquisition” of the diagnostics company. Since acquisition rumors emerged Wednesday,...
BC Extra | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

FDA’s approval Friday of Rybelsus, the first oral GLP-1R agonist for diabetes, brings across the finish line a critical drug for Novo Nordisk’s growth strategy after the company prioritized best-in-class R&D three years ago. After...
BC Extra | Jun 11, 2019
Clinical News

June 10 Clinical Quick Takes: Oral semaglutide superior to Jardiance, non-inferior to Victoza; plus Aptinyx and Eli Lilly

Novo’s oral semaglutide meets in Phase III trials  Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported results from two Phase III trials of its oral semaglutide in Type II diabetes. In PIONEER 2, oral semaglutide, a...
BC Extra | May 3, 2019
Company News

May 3 Company Quick Takes: NHS England, Acacia, Insys, Novo, AZ

NHS strikes deal aimed at eliminating HCV in England  NHS England partnered with Gilead Sciences Inc. (NASDAQ:GILD), Merck & Co. Inc. (NYSE:MRK) and AbbVie Inc. (NYSE:ABBV) to identify and treat individuals who are unaware they...
BC Innovations | Mar 13, 2019
Distillery Therapeutics

A PYY-IgG conjugate for obesity

DISEASE CATEGORY: Endocrine/Metabolic INDICATION: Obesity Mouse and non-human primate studies suggest a PYY-IgG conjugate could help treat obesity. The fusion protein consists of a 33-amino acid PYY fragment that promotes satiation linked to an IgG...
BC Innovations | Jan 3, 2019
Distillery Therapeutics

Endocrine/metabolic

INDICATION: Obesity Cell culture, mouse and non-human primate (NHP) studies suggest inhibiting the GIP receptor alone or in combination with GLP-1R agonists could help treat obesity. In a mouse model of diet-induced obesity, a mouse...
BioCentury | Nov 9, 2018
Product Development

Cashing out CVOT

Whether or how much diabetes companies will save by dropping postmarket cardiovascular outcomes trials, if FDA follows the advice of its advisory committee, could boil down to what target they are pursuing and whether they...
BC Week In Review | Aug 10, 2018
Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Aug. 8 after reporting narrowing U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower...
BC Extra | Aug 8, 2018
Company News

Novo Nordisk's Tresiba, Victoza sales disappoint amid sliding U.S. sales

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) shares dipped Wednesday after reporting declining U.S. sales and disappointing revenues for diabetes drugs Tresiba insulin degludec and Victoza liraglutide in its 2Q18 earnings. Novo also predicted lower U.S....
BC Week In Review | Jun 22, 2018
Clinical News

Novo's oral GLP-1 analog meets primary in Phase IIIa trials compared with approved therapies

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral diabetes candidate semaglutide was at least non-inferior to two approved therapies in reducing HbA1c and led to greater body weight reductions than both drugs in a...
Items per page:
1 - 10 of 378